TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8797468
Drug: Acetyl-L-carnitine hydrochloride
Normalized name: Acetyl-L-carnitine hydrochloride
DrugBank: Acetylcarnitine (DB08842)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl-L-carnitine hydrochloride (ALCAR)
Study: 1521671
Drug: 20 mg/day
Normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day zolpidem
Study: 1521671
Drug: 10 mg/day
Normalized name: Adlarity 10 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/day zolpidem
Study: 29913528
Drug: Camphor-Crataegus Combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camphor-Crataegus Combination (CCC) - 20 drops of a fixed combination of natural D-camphor and an ethanolic extract from fresh Crataegus berries
Study: 22385586
Drug: Educational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Educational intervention (written and oral program on hypertension and cardiovascular risk)
Study: 31959492
Drug: Olaparib 50
Normalized name: olaparib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib 50 mg BID
Study: 31959492
Drug: Olaparib 100
Normalized name: olaparib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib 100 mg BID
Study: 31959492
Drug: Olaparib 200
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib 200 mg BID
Study: 31959492
Drug: IV paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV paclitaxel 135 mg/m2/3 h + IV bevacizumab 15 mg/kg + IP cisplatin 75 mg/m2 + IP paclitaxel 60 mg/m2
Study: 31959492
Drug: Maintenance olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Maintenance olaparib 300 mg BID and bevacizumab 15 mg/kg Day 1
Study: 19248193
Drug: Telmisartan (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan (20 mg o.d.)
Study: 19248193
Drug: Valsartan (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (80 mg o.d.)
Study: 20659194
Drug: Oral cryotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cryotherapy
Study: 17393189
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral care (Control)
Study: 3195995
Drug: Trimethoprim-sulfamethoxazole (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole (160 mg of trimethoprim and 800 mg of sulfamethoxazole orally, twice daily)
Study: 29741660
Drug: Provider-chosen dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Provider-chosen dose of morphine
Study: 26151785
Drug: Efinaconazole topical
Normalized name: efinaconazole topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efinaconazole topical solution, 10%
Study: 24649785
Drug: Acetaminophen 500
Normalized name: acetaminophen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 500 mg three times per day
Study: 18161012
Drug: THC (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC (60 mg/day)
Study: 18161012
Drug: Lofexidine (2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lofexidine (2.4 mg/day)
Study: 12648028
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg immediate‐release tablet of ximelagatran with breakfast
Study: 12648028
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg immediate‐release tablet of ximelagatran while fasting
Study: 12648028
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg subcutaneous injection of ximelagatran
Study: 12648028
Drug: 2mg intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2mg intravenous infusion of melagatran
Study: 9695300
Drug: Nebulized salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized salbutamol (0.15 mg/kg in 2 mL saline)
Study: 7867139
Drug: Daily regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily regimen of amphotericin B (escalating dose starting at 0.05 mg/kg to 1 mg/kg, total dose of 20 mg/kg)
Study: 7867139
Drug: Alternate-day regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternate-day regimen of amphotericin B (escalating dose starting at 0.05 mg/kg to 1 mg/kg, then given on alternate days)
Study: 21406646
Drug: High-dose clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose clopidogrel (600-mg initial dose, 150 mg daily thereafter)
Study: 21406646
Drug: Standard-dose clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose clopidogrel (no additional loading dose, 75 mg daily)
Study: 23517020
Drug: High-dose clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose clopidogrel
Study: 23517020
Drug: Standard-dose clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose clopidogrel
Study: 9488197
Drug: Amlodipine-lovastatin combination
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine-lovastatin combination therapy
Study: 28697676
Drug: Laser therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser therapy (LST)
Study: 9085534
Drug: Oral appliance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral appliance therapy (OA)
Study: 27126223
Drug: Axial implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axial implants (2 anterior/2 posterior)
Study: 27126223
Drug: Tilted implants
Normalized name: TILT-123
DrugBank: TILT-123 (DB17519)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tilted implants (2 anterior axial/2 distal tilted)
Study: 24686029
Drug: USG‐PVB with
Approvals — FDA: no, EMA: no, PMDA: no
Description: USG‐PVB with 30 mL of 0.5% ropivacaine (3 injections of 10 mL each at right T5 and bilateral T8)
Study: 24686029
Drug: USG‐PVB with
Approvals — FDA: no, EMA: no, PMDA: no
Description: USG‐PVB with 30 mL of 0.5% ropivacaine
Study: 24686029
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline injection of 10 mL at every site (control group)
Study: 22612662
Drug: Rectal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal misoprostol (600 µg)
Study: 16362784
Drug: Normal oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal oral mucosa
Study: 1897350
Drug: Indomethacin infusion
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin infusion
Study: 6349411
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine (2 mg in 10 ml of normal saline)
Study: 28723852
Drug: Skin barrier
Normalized name: Skin Barrier
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin barrier cream applied 3 times a day
Study: 24894026
Drug: Thirst bundle
Normalized name: oxymetazoline
DrugBank: Oxymetazoline (DB00935)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thirst bundle (oral swab wipes, sterile ice-cold water sprays, lip moisturizer)
Study: 17961421
Drug: Carvedilol (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (target dose of 50 mg/d, actual achieved dose 36.25 +/- 14.31 mg/d in group 1 and 25.97 +/- 8.83 mg/d in group 2)
Study: 16053779
Drug: Carvedilol treatment
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carvedilol treatment
Study: 9509226
Drug: Apply nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply nitroglycerin ointment and stop i.v. nitroglycerin 30 minutes later
Study: 9509226
Drug: Decrease the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decrease the dose of i.v. nitroglycerin by 10 micrograms/min every 15 minutes, apply one half the dose of nitroglycerin ointment when the original i.v. dose has been decreased by one half, and apply the full dose of the ointment when the i.v. nitroglycerin is stopped
Study: 31085860
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Normal Saline and Ringer's Lactate (NS + RL)
Study: 23411526
Drug: Mechanical preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical preparation
Study: 16428920
Drug: Ultrahaler (DPI)
Normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ultrahaler (DPI) with doses of 130 and 360 microg/actuation
Study: 16428920
Drug: MDI (metered
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDI (metered dose inhaler) with doses of 75 and 225 microg/actuation
Study: 16428920
Drug: Ultrahaler (DPI)
Normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ultrahaler (DPI) with new dose strengths of 100, 225, and 450 microg/actuation
Study: 8181198
Drug: Fast infusion
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast infusion of temazepam (0.4 mg/kg in 30 minutes)
Study: 8181198
Drug: Slow infusion
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow infusion of temazepam (0.4 mg/kg in 120 minutes)
Study: 8181198
Drug: Placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control (vehicle infusion similar to fast infusion)
Study: 3422553
Drug: Ethanol (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.75 mL/kg)
Study: 3422553
Drug: Ethanol (1.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (1.1 mL/kg)
Study: 25311594
Drug: Intensive voice
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive voice therapy
Study: 31630089
Drug: Cognitive Functional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Functional Therapy (CFT)
Study: 31427344
Drug: Cognitive Functional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Functional Therapy plus movement sensor biofeedback
Study: 15774791
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy + muramyl tripeptide (MTP)
Study: 15774791
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy + ifosfamide
Study: 7722020
Drug: Terbinafine 250
Normalized name: terbinafine 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine 250 mg/day for 16 weeks
Study: 7722020
Drug: Griseofulvin 500
Normalized name: griseofulvin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Griseofulvin 500 mg/day for 52 weeks
Study: 2351367
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg of perindopril tert‐butylamine salt by oral route (treatment A)
Study: 2351367
Drug: Intravenous route
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous route (bolus in 5 min, treatment B)
Study: 2351367
Drug: Equimolar dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Equimolar dose of perindoprilat (6.1 mg) by intravenous route (infusion over 2 h, treatment C)
Study: 30385649
Drug: Very Low
Normalized name: Very low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very Low Nicotine Content (VLNC) cigarettes (0.4 mg nicotine/g tobacco)
Study: 31867650
Drug: Normal nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Normal nicotine content cigarettes (15.8 mg/g)
Study: 18378608
Drug: Celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 mg BID
Study: 17460158
Drug: Naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen sodium 220 mg BID
Study: 14693591
Drug: 45 mg
Normalized name: lutein 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 mg 2-chloroprocaine with epinephrine
Study: 350495
Drug: Aspirin (3.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (3.9 g daily)
Study: 31422655
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of 0.25% bupivacaine
Study: 11473840
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of 1% lidocaine
Study: 31422655
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL of 0.25% bupivacaine plus 5 mL of 1% lidocaine
Study: 23850416
Drug: HSV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSV vaccine (AS04-adjuvanted herpes simplex virus type 2 glycoprotein D subunit vaccine)
Study: 23850416
Drug: Hepatitis A
Normalized name: HEPATITIS A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis A vaccine (Havrix™; HAV control)
Study: 19824016
Drug: 25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g unground flaxseed
Study: 19824016
Drug: 25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g sesame seed
Study: 19824016
Drug: 12.5 g
Normalized name: glycerin 12.5 GM per 20.4 ML Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 g unground flaxseed + 12.5 g sesame seed (flaxseed+sesame seed bar, FSB)
Study: 19242131
Drug: 40 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mL/kg of fluid over 15 minutes followed by dopamine
Study: 19242131
Drug: 20 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL/kg over 20 minutes up to a maximum of 60 mL/kg over 1 hour followed by dopamine
Study: 15198901
Drug: GOS supplemented
Normalized name: Go-dry
Approvals — FDA: no, EMA: no, PMDA: no
Description: GOS supplemented formula (0.24 g/dl)
Study: 12374874
Drug: Heparin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin plus placebo
Study: 234668
Drug: Timolol (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol (30 mg per day)
Study: 6130038
Drug: Propranolol (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (120 mg per day)
Study: 27025337
Drug: Empirical tuberculosis
Normalized name: Mycobacterium tuberculosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical tuberculosis therapy
Study: 23954450
Drug: Isoniazid preventive
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid preventive therapy
Study: 22697273
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of Lobeglitazone and Metformin
Study: 17361245
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment periods for timolol GFS
Study: 16379620
Drug: AIR pulmonary
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AIR pulmonary delivery system (5-mg placebo powder of engineered particles)
Study: 18540781
Drug: Olanzapine 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 5.0 mg
Study: 6144462
Drug: Lorazepam 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam 1.0 mg
Study: 9860397
Drug: CCK-8 infused
Normalized name: CCK-8
DrugBank: Sincalide (DB09142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CCK-8 infused intravenously (i.v.) at physiological doses
Study: 9860397
Drug: Loxiglumide (CCK-A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loxiglumide (CCK-A receptor antagonist) pretreatment
Study: 7658089
Drug: CVD 112
Normalized name: Vibrio cholerae CVD 103-HGR strain live antigen Oral Suspension [Vaxchora]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVD 112 vaccine (10^6 cfu)
Study: 7658089
Drug: CVD 112
Normalized name: Vibrio cholerae CVD 103-HGR strain live antigen Oral Suspension [Vaxchora]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVD 112 vaccine
Study: 2527546
Drug: Cilazapril and
Normalized name: cilazapril and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril and Hydrochlorothiazide (combination)
Study: 1104411
Drug: Prednisone 20
Normalized name: prednisone 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 20 mg daily (Pred)
Study: 1104411
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of prednisone 10 mg and azathioprine 50 mg daily (Comb)
Study: 28527657
Drug: Brief guided
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief guided parent-delivered cognitive behavioural therapy (CBT)
Study: 28527657
Drug: Solution-focused brief
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solution-focused brief therapy
Study: 24764200
Drug: Paroxetine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (10 mg/d) coadministration
Study: 15045129
Drug: Enoxaparin 1
Normalized name: ENOXAPARIN 100MG/ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 1 mg/kg BW s.c. b.i.d.
Study: 15045129
Drug: i.v. heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. heparin aPTT‐adjusted daily for 8 +/- 2 days
Study: 7962286
Drug: Prolonged dopamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged dopamine infusion (5 micrograms/kg.min, iv)
Study: 7962286
Drug: Brief dopamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief dopamine administration (15‐ to 21‐h)
Study: 16508259
Drug: Dopamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine infusion
Study: 3604396
Drug: Live rubella
Normalized name: Rubella, live attenuated
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live rubella vaccine
Study: 23312567
Drug: Iloperidone (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iloperidone (24 mg/d, mean dose = 21.6 mg)
Study: 23312567
Drug: Iloperidone (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iloperidone (12 mg/d, given once daily at bedtime)
Study: 18458356
Drug: Sodium Bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium Bicarbonate (NaHCO(3)) 0.3 g/kg
Study: 12665753
Drug: Epinephrine injection
Normalized name: epinephrine Injection
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine injection plus heat probe coagulation
Study: 12665753
Drug: Epinephrine injection
Normalized name: epinephrine Injection
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine injection plus argon plasma coagulation
Study: 19263664
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of fluor gel
Study: 11207224
Drug: Restrictive red
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive red blood cell transfusion guidelines without erythropoietin administration
Study: 18760492
Drug: Erythropoietin administration
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin administration
Study: 9681219
Drug: Chemotherapy (ABVD:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (ABVD: adriamycin, bleomicin, vinblastine and dacarbazine, 6 monthly cycles)
Study: 8008405
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of morphine
Study: 2809191
Drug: Ketanserin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (20 or 40 mg twice a day for 12 weeks)
Study: 6137857
Drug: Zopiclone 5
Normalized name: zopiclone 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zopiclone 5 mg
Study: 6996815
Drug: Zopiclone 9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zopiclone 9 mg
Study: 6996815
Drug: Zopiclone 13.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zopiclone 13.5 mg
Study: 6996815
Drug: Zopiclone (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zopiclone (all doses)
Study: 31476741
Drug: L-Amino Acid
Normalized name: L-α-amino-γ-methylmercaptobutyric acid
DrugBank: Methionine (DB00134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-Amino Acid (L-AA)
Study: 31476741
Drug: L-AA and
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-AA and CGMP-AA (immediate post-consumption)
Study: 28330721
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (20,000 IU weekly)
Study: 25082115
Drug: Integrative cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative cognitive behavioural therapy for prolonged grief (PG‐CBT), 20‐25 sessions
Study: 2927990
Drug: Low-dose nebulized
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose nebulized albuterol (0.05 mg/kg per dose)
Study: 31331773
Drug: Pentavac SD®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentavac SD® vaccine
Study: 23425751
Drug: Daily administration
Normalized name: Prevpac 30mg-500mg-500mg Daily Administration Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily administration of the Confusion‐Assessment Method for ICU (intervention service)
Study: 2644923
Drug: Extended course
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended course of moxalactam (1 g intravenously for eight doses)
Study: 2644923
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (single dose and extended course)
Study: 1090358
Drug: Oral 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral 5-FU (20 mg/kg/day for 5 days)
Study: 1090358
Drug: Intravenous 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous 5-FU (13.5 mg/kg/day for 5 days)
Study: 1090358
Drug: Oral 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral 5-FU (for malignant hepatomegaly)
Study: 1090358
Drug: Intravenous 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous 5-FU (for malignant hepatomegaly)
Study: 21947318
Drug: Pregabalin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (300 mg/day)
Study: 26721012
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A - Lingual flap retraction in addition to buccal flap
Study: 17909718
Drug: Steroid group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid group (30 mg/kg BW methylprednisolone intravenously)
Study: 14973302
Drug: Telithromycin (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telithromycin (any dosage)
Study: 3554085
Drug: Postoperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative chemotherapy (MeCCNU + 5‐FU)